Guido Claessen1, Andre La Gerche2, Jean-Yves Wielandts1, Jan Bogaert3, Johan Van Cleemput1, Wim Wuyts4, Piet Claus5, Marion Delcroix4, Hein Heidbuchel6. 1. Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium University Hospitals Leuven, Leuven, Belgium. 2. Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium St Vincent's Hospital, University of Melbourne, Fitzroy, Australia. 3. University Hospitals Leuven, Leuven, Belgium Department of Imaging & Pathology, University of Leuven, Leuven, Belgium. 4. University Hospitals Leuven, Leuven, Belgium Department of Clinical and Experimental Medicine, University of Leuven, Leuven, Belgium. 5. Department of Clinical and Experimental Medicine, University of Leuven, Leuven, Belgium. 6. University of Hasselt and Heart Center, Jessa Hospital, Hasselt, Belgium.
Abstract
OBJECTIVES: Symptoms in patients with chronic thromboembolic pulmonary hypertension (CTEPH) predominantly occur during exercise, while haemodynamic assessment is generally performed at rest. We hypothesised that exercise imaging of RV function would better explain exercise limitation and the acute effects of pulmonary vasodilator administration than resting measurements. METHODS: Fourteen patients with CTEPH and seven healthy control subjects underwent cardiopulmonary testing to determine peak exercise oxygen consumption (VO2peak) and ventilatory equivalent for carbon dioxide (VE/VCO2) at the anaerobic threshold. Subsequently, cardiac MRI was performed at rest and during supine bicycle exercise with simultaneous invasive measurement of mean pulmonary arterial pressure (mPAP) before and after sildenafil. RESULTS: During exercise, patients with CTEPH had a greater increase in the ratio of mPAP relative to cardiac output (CO) than controls (6.7 (5.1-8.7) vs 0.94 (0.86-1.8) mm Hg/L/min; p < 0.001). Stroke volume index (SVi) and RVEF increased during exercise in controls, but not in patients with CTEPH (interaction p < 0.001). Sildenafil decreased the mPAP/CO slope and increased SVi and RVEF in patients with CTEPH (p < 0.05) but not in controls. In patients with CTEPH, RVEF reserve correlated moderately with VO2peak (r = 0.60; p = 0.030) and VE/VCO2 (r = -0.67; p = 0.012). By contrast, neither VO2peak nor VE/VCO2 correlated with resting RVEF. CONCLUSIONS: Exercise measures of RV function explain much of the variance in the exercise capacity of patients with CTEPH while resting measures do not. Sildenafil increases SVi during exercise in patients with CTEPH, but not in healthy subjects. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES: Symptoms in patients with chronic thromboembolic pulmonary hypertension (CTEPH) predominantly occur during exercise, while haemodynamic assessment is generally performed at rest. We hypothesised that exercise imaging of RV function would better explain exercise limitation and the acute effects of pulmonary vasodilator administration than resting measurements. METHODS: Fourteen patients with CTEPH and seven healthy control subjects underwent cardiopulmonary testing to determine peak exercise oxygen consumption (VO2peak) and ventilatory equivalent for carbon dioxide (VE/VCO2) at the anaerobic threshold. Subsequently, cardiac MRI was performed at rest and during supine bicycle exercise with simultaneous invasive measurement of mean pulmonary arterial pressure (mPAP) before and after sildenafil. RESULTS: During exercise, patients with CTEPH had a greater increase in the ratio of mPAP relative to cardiac output (CO) than controls (6.7 (5.1-8.7) vs 0.94 (0.86-1.8) mm Hg/L/min; p < 0.001). Stroke volume index (SVi) and RVEF increased during exercise in controls, but not in patients with CTEPH (interaction p < 0.001). Sildenafil decreased the mPAP/CO slope and increased SVi and RVEF in patients with CTEPH (p < 0.05) but not in controls. In patients with CTEPH, RVEF reserve correlated moderately with VO2peak (r = 0.60; p = 0.030) and VE/VCO2 (r = -0.67; p = 0.012). By contrast, neither VO2peak nor VE/VCO2 correlated with resting RVEF. CONCLUSIONS: Exercise measures of RV function explain much of the variance in the exercise capacity of patients with CTEPH while resting measures do not. Sildenafil increases SVi during exercise in patients with CTEPH, but not in healthy subjects. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Timothy J Roberts; Andrew T Burns; Richard J MacIsaac; Andrew I MacIsaac; David L Prior; André La Gerche Journal: J Appl Physiol (1985) Date: 2019-05-02
Authors: Toby Rogers; Kanishka Ratnayaka; Jaffar M Khan; Annette Stine; William H Schenke; Laurie P Grant; Jonathan R Mazal; Elena K Grant; Adrienne Campbell-Washburn; Michael S Hansen; Rajiv Ramasawmy; Daniel A Herzka; Hui Xue; Peter Kellman; Anthony Z Faranesh; Robert J Lederman Journal: J Cardiovasc Magn Reson Date: 2017-07-27 Impact factor: 5.364
Authors: Timothy J Roberts; Andrew T Burns; Richard J MacIsaac; Andrew I MacIsaac; David L Prior; André La Gerche Journal: Cardiovasc Diabetol Date: 2018-03-23 Impact factor: 9.951
Authors: Andreas J Rieth; Manuel J Richter; Alexander Berkowitsch; Marc Frerix; Ingo H Tarner; Veselin Mitrovic; Christian W Hamm Journal: PLoS One Date: 2018-09-20 Impact factor: 3.240
Authors: Frederik Helsen; Piet Claus; Alexander Van De Bruaene; Guido Claessen; André La Gerche; Pieter De Meester; Mathias Claeys; Charlien Gabriels; Thibault Petit; Béatrice Santens; Els Troost; Jens-Uwe Voigt; Jan Bogaert; Werner Budts Journal: J Am Heart Assoc Date: 2018-10-16 Impact factor: 5.501
Authors: M C J van Thor; R J Lely; N J Braams; L Ten Klooster; M A M Beijk; R H Heijmen; D A F van den Heuvel; B J W M Rensing; R J Snijder; A Vonk Noordegraaf; E J Nossent; L J Meijboom; P Symersky; J J Mager; H J Bogaard; M C Post Journal: Neth Heart J Date: 2020-02 Impact factor: 2.380